Standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract is under clinical development by ALK-Abello and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract’s likelihood of approval (LoA) and phase transition for Allergic Asthma took place on 05 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract overview
House dust mite [Dermatophagoides pteronyssinus and Dermatophagoides farinae] (MK-8237, MITIZAX, Miticure, Odactra, ALK house dust mites vaccine, Acarizax) acts as antiallergic and immunizing preparation. It is formulated as oral lyophilisate tablet-based allergy vaccine, administered sublingually or oral route. It is indicated for treatment of allergic rhinitis and allergic asthma and house dust mite allergy. Miticure is indicated in adults and adolescents (12-64 years) as hyposensitisation therapy (allergy immunotherapy) for the treatment of allergic rhinitis caused by house dust mites and in paediatric patients aged 5-17 with HDM-induced allergic rhinitis. Acarizax also indicated for the treatment of adolescent patients (12-17 years of age) with HDM-induced allergic rhinitis. Odactra is indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis in adults 18 through 65 years of age, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts.
It is under development for the prevention of house dust mite-induced rhinoconjunctivitis and allergic asthma.
It was under development for the treatment of allergic rhinitis, house dust mite allergy and allergic rhino-conjunctivitis.
ALK-Abello (ALK), a subsidiary of The Lundbeck Foundation, discovers, develops, and commercializes immunotherapies for the treatment and prevention of allergies. The company’s allergy immunotherapy product portfolio includes tablets, sublingual or drop-based vaccines, subcutaneous vaccines, and adrenaline auto-injectors to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing ragweed, house dust mite, and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, and venom, among others. The company has subsidiaries in Europe, North America, and Asia-Pacific. ALK is headquartered in Horsholm, Denmark .
Quick View Standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract LOA Data
|Highest Development Stage|